ARTBIO expands board and establishes technical advisory board
Ella Day | August 11, 2025 | Appointment | Medical Communications, Research and Development | ARTBIO, Corporate, Oncology, advisory board, radiopharmaceuticals
ARTBIO, a radiopharma company developing radioligand therapies (RLTs), has appointed four new members to its board of directors and formed a technical advisory board.
Firstly, Maha Katabi (pictured top left), a general partner at Sofinnova Investments, with more than 20 years’ experience in biotech leadership and investment, has been appointed. Robert Mittendorff (pictured top right), general partner and head of healthcare at B Capital Group, joins with a background in clinical medicine and life sciences investment.
Independent director, Julie O’Neill (pictured bottom right), brings a wealth of experience from senior leadership roles at Alexion Pharmaceuticals and Gilead Sciences and as well her position as chair of Ireland’s National Institute for Bioprocessing Research and Training. Gabe Gelman (pictured bottom left), who is head of capital solutions at Baker Bros Advisors, also joins the new board.
“Following our recent Series B funding round, these appointments will enable ARTBIO to rapidly advance multiple programs designed to have the highest patient impact,” said Ted Love, board chair.
Co-founder of the company, Roy Larsen, will step down from the board to join the new technical advisory board. He is known for his contributions to radiopharmaceutical development,
“Larsen is a pillar of the radiopharma field – thousands of patients have benefitted from his inventions already,” said CEO Emanuele Ostuni. “His innovations will continue to have a positive impact on ARTBIO and the RLT industry for decades to come.”
ARTBIO’s lead programme, AB001, has entered human studies for metastatic castration-resistant prostate cancer.
Ella Day
11/8/25
This article featured in: September 2025 – The Pharmafile Brief
Related Content
VIVES Partners contributes to €84m funding for radiopharma company, Nuclidium
VIVES Partners, the managing company of VIVES Funds, has announced that it will contribute to …
Tozaro forms Technical Advisory Board to accelerate Smart Polymer commercialisation for CGT bioprocessing
Tozaro, a UK-based biopharma focused on cell and gene therapy (CGT), has announced the formation …
